VAXDYN | KAPAVAX (VXD-005) | 1a | Vaccine | Precise Pathogen ID Priority Pathogen * Community acquired pneumonia (CAP) and other upper respiratory infections (URTI) (sinusitis/otitis media etc) | New Class New Target New MoA | Pre-clinical |
Spexis AG | LptA-OMPTA | 3a | Protein/Peptide | Gram - Priority Pathogen * Complicated urinary tract infections (cUTI) | New Class New Target New MoA | Lead opt |
F2G Ltd | Olorofim | 3a | NME | Precise Pathogen ID Aspergillosis refractory, resistant or intolerant to currently available therapy. Infections due to Lomentospora prolificans, Scedosporium, Fusarium and Scopulariopsis species. Treatment of coccidioidomycosis refractory or otherwise unable to be treated with standard of care therapy. | New Class New Target | Phase II |
AdjuTec Pharma AS | APC148 | 3d | NME | Gram - Priority Pathogen * MBL-CRE | New Class New MoA | Pre-clinical |
Diotheris SAS | DECOLONIZE | 1b | Other | Precise Pathogen ID Priority Pathogen * Decolonization of S.aureus MR | New Class New Target New MoA | Discovery |
Diotheris SAS | PREVENT | 1b | Other | Precise Pathogen ID Priority Pathogen * Prevent infection by S.aureus MR | New Class New Target New MoA | Pre-clinical |
Aptorum Group Ltd | ALS-3 | 3d | Other | Gram + Priority Pathogen * Reviving existing antibiotics to overcome drug Resistance | New Class New Target New MoA | Lead opt |
Aptorum Group Ltd | ALS-2 | 4a | Other | Gram + Priority Pathogen * Treatment of bacterial infections casued by Gram Positive Bacteria including Staphylococcus aureus (MRSA) | New Class New Target New MoA | Lead opt |
Aptorum Group Ltd | ALS-1 | 3a | Other | Precise Pathogen ID Priority Pathogen * Treatment of viral infections casued by influenza virus A | New Class New Target New MoA | Lead opt |
Aptorum Group Ltd | ALS-4 | 3c | Other | Precise Pathogen ID Priority Pathogen * Treatment of bacterial infections casued by Staphylococcus aureus infections including MRSA | New Class New Target New MoA | Pre-clinical |
Debiopharm International | 1454/S | 3a | NME | Gram - Priority Pathogen * Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | New Class New Target New MoA | Lead opt |
OLGRAM | Ol20-01 | | Protein/Peptide | Broad Gram +/- Priority Pathogen * Infectious relapses | New Class New MoA | Pre-clinical |
Selmod GmbH | slm 500 | 3a | NME | Broad Gram +/- Priority Pathogen * | New Class New Target New MoA | Pre-clinical |
Selmod GmbH | slm 400 | 3a | NME | Gram - Priority Pathogen * | New Class New Target New MoA | Discovery |
Selmod GmbH | slm 300 | 3a | NME | Gram - Priority Pathogen * | New Class New Target New MoA | Discovery |
Selmod GmbH | slm 200 | 3a | NME | Precise Pathogen ID Priority Pathogen * C.C. albicans, flucanozole-resistant; Drug-resistant Aspergillus; Drug-resistant C. auris | New MoA | Lead opt |
Selmod GmbH | slm 100 | 3a | NME | Precise Pathogen ID Priority Pathogen * C. albicans, flucanozole-resistant; Drug-resistant Aspergillus; Drug-resistant C. auris | New Class New Target New MoA | Lead opt |
BioNTech R&D | PM-477 | 3a | Protein/Peptide | Precise Pathogen ID Endolysin specific to bacteria of the genus Gardnerella to treat Bacterial Vaginosis | New Target | Lead opt |
Nabriva Therapeutics GmbH | BC-2126 | 3a | NME | Gram - Priority Pathogen * Respiratory tract infections caused by P. aeruginosa, A. baumannii and Burkholderia cepacia complex | New Class New MoA | Pre-clinical |
Nabriva Therapeutics GmbH | BC-7013 | 3a | NME | Broad Gram +/- Priority Pathogen * Topical treatment of skin and skin structure infections | | Phase I |
Destiny Pharma plc | XF-73 | 3a | NME | Broad Gram +/- Priority Pathogen * Dermal wound infections | New Class New Target New MoA | Phase I |
AiCuris Anti-infective Cures AG | NPI Scaffolds | 3a | NME | Gram - Priority Pathogen * Undisclosed | New Class New Target New MoA | Discovery |
AiCuris Anti-infective Cures AG | Macrocyles | 3a | NME | Gram - Priority Pathogen * Undisclosed | New Class New Target New MoA | Discovery |
Basilea | undisclosed | 3a | NME | Gram - Priority Pathogen * Serious infections in hospitalized patients | New Class | Lead opt |
Basilea | Non beta-lactam PBP inhibitor | 3a | NME | Gram - Priority Pathogen * Serious infections in hospitalized patients | New Class | Lead opt |
Pherecydes Pharma | PP1151 | 3a | Phage | Precise Pathogen ID Priority Pathogen * MDR infections to Escherichia coli | New Class New MoA | Pre-clinical |
Pherecydes Pharma | PP1002 | 3a | Phage | Precise Pathogen ID Priority Pathogen * MDR infections to Escherichia coli | New Class New MoA | Pre-clinical |
Pherecydes Pharma | PP970 | 3a | Phage | Precise Pathogen ID Priority Pathogen * MDR infections to Escherichia coli | New Class New MoA | Pre-clinical |
Pherecydes Pharma | PP954 | 3a | Phage | Precise Pathogen ID Priority Pathogen * MDR infections to Escherichia coli | New Class New MoA | Pre-clinical |
Pherecydes Pharma | PP814 | 3a | Phage | Precise Pathogen ID Priority Pathogen * MDR infections to Escherichia coli | New Class New MoA | Pre-clinical |
Pherecydes Pharma | PP700 | 3a | Phage | Precise Pathogen ID Priority Pathogen * MDR infections to Escherichia coli | New Class New MoA | Pre-clinical |
Assuré Medical Limited | Sol-UTI | 1b | Other | Gram - Priority Pathogen * Recurrent Urinary Tract Infection (rUTI) | New Target New MoA | Pre-clinical |
BioVersys AG | BV100 | 3a | NME | Gram - Priority Pathogen * A. baumannii (HAP,VAP, BSI) | New MoA | Phase I |
Madam Therapeutics BV | P10 | 3a | Protein/Peptide | Broad Gram +/- Priority Pathogen * Veterinary Diseases (companion animals and lifestock) | New Class New Target New MoA | Pre-clinical |
Destiny Pharma plc | DPD-207 | 3a | NME | Gram + Priority Pathogen * MDR bacterial eye infections | New Class New Target New MoA | Pre-clinical |
Alphanosos | W9P154 | 3e | Other | Precise Pathogen ID Priority Pathogen * Tuberculosis, Buruli Ulcer | New Class New Target New MoA | Lead opt |
ABAC therapeutics | ABAC-40,244 | 3a | NME | Precise Pathogen ID Priority Pathogen * Infections by MDR/XDR Staph aureus | New Class New Target New MoA | Lead opt |
ABAC therapeutics | ABAC-40105 | 3a | NME | Gram - Priority Pathogen * Infections by MDR/XDR A baumannii, including ColistinR and CarbapenemR | New Class New Target New MoA | Lead opt |
ANTABIO S.A.S | ANT3310 | 3d | NME | Gram - Priority Pathogen * Hospital-acquired infections caused by carbapenem-resistant Enterobacteriaceae (CRE) and Acinetobacter [cUTI, cIAI, Nosocomial Pneumonia] | New MoA | Pre-clinical |
VibioSphen | Sativa | 3b | NME | Pulmonary infection, UTI | | Pre-clinical |
VAXDYN | ACINETOVAX (VXD-001) | 1a | Vaccine | Precise Pathogen ID Priority Pathogen * Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | New Class New Target New MoA | Pre-clinical |
Summit Therapeutics plc | SMT026571 | 3a | NME | Gram - Priority Pathogen * Gonorrhoea infection | New Class New Target New MoA | Pre-clinical |
Summit Therapeutics plc | Ridinilazole | 3a | NME | Gram + Priority Pathogen * Clostridium difficile infection | New Class New Target New MoA | Phase III |
QureTech Bio AB | TIB | 3a | NME | Precise Pathogen ID Trachoma, Chlamydia eye infection | New Class New Target New MoA | Lead opt |
QureTech Bio AB | GmP | 3d | NME | Gram + Priority Pathogen * VRE and MRSA | New Class New Target New MoA | Lead opt |
QureTech Bio AB | CIB | 3a | NME | Precise Pathogen ID Priority Pathogen * Genital Chlamydia infection | New Class New Target New MoA | Lead opt |
QureTech Bio AB | MTI | 3d | NME | Precise Pathogen ID Priority Pathogen * MDR Tuberculosis | New Class New Target New MoA | Pre-clinical |
Spexis AG | Murepavadin (inhaled) | 3a | Protein/Peptide | Gram - Priority Pathogen * Cystic fibrosis associated infections | New Class New Target New MoA | IND/CTA ready |
Spexis AG | BamA-OMPTA | 3a | Protein/Peptide | Gram - Priority Pathogen * Hospitalacquired or Ventilatoracquired bacterial pneumoniae (HABP/VABP) | New Class New Target New MoA | Lead opt |
Phico Therapeutics Ltd | SASPject™ PT4 | 3a | Other | Precise Pathogen ID Priority Pathogen * Serious Klebsiella Pneumoniae infections where treatment options are limited | New Target New MoA | Pre-clinical |
Phico Therapeutics Ltd | SASPject™ PT5 | 3a | Other | Precise Pathogen ID Priority Pathogen * Serious E.coli infections where treatment options are limited | New Target New MoA | Pre-clinical |
Phico Therapeutics Ltd | SASPject™ PT3.8 | 3a | Other | Precise Pathogen ID Priority Pathogen * Serious Pseudomonas Aeruginosa infections where treatment options are limited | New Target New MoA | Pre-clinical |
Pherecydes Pharma | PN1777 | 3a | Phage | Precise Pathogen ID Priority Pathogen * MDR infections to Pseudomonas aeruginosa | New Class New MoA | Pre-clinical |
Pherecydes Pharma | PN1792 | 3a | Phage | Precise Pathogen ID Priority Pathogen * MDR infections to Pseudomonas aeruginosa | New Class New MoA | Pre-clinical |
Pherecydes Pharma | PN1797 | 3a | Phage | Precise Pathogen ID Priority Pathogen * MDR infections to Pseudomonas aeruginosa | New Class New MoA | Pre-clinical |
Pherecydes Pharma | PN1493 | 3a | Phage | Precise Pathogen ID Priority Pathogen * MDR infections to Staphylococcus aureus | New Class New MoA | Pre-clinical |
Pherecydes Pharma | PN1815 | 3a | Phage | Precise Pathogen ID Priority Pathogen * MDR infections to Staphylococcus aureus | New Class New MoA | Pre-clinical |
Pherecydes Pharma | PN1957 | 3a | Phage | Precise Pathogen ID Priority Pathogen * MDR infections to Staphylococcus aureus | New Class New MoA | Pre-clinical |
Pherecydes Pharma | PN1450 | 3a | Phage | Precise Pathogen ID Priority Pathogen * MDR infections to Pseudomonas aeruginosa | New Class New MoA | Pre-clinical |
BioNTech R&D | PhM398 | 3a | Phage | Precise Pathogen ID Priority Pathogen * Periprosthetic Joint Infections | New Class New MoA | Lead opt |
BioNTech R&D | PhM754 | 3a | Phage | Precise Pathogen ID Priority Pathogen * Urinary Tract Infections | New Class New MoA | Lead opt |
Omnix Medical | OMN6 | 3a | Protein/Peptide | Gram - Priority Pathogen * A. baumannii induced Bacteremia or HABP or VABP | New Class New MoA | Lead opt |
NovaBiotics Ltd | Novamycin® | 3a | Protein/Peptide | Non Bacterial Target Priority Pathogen * Invasive Fungal Disease, mucocutaneous fungal infections | New Class New Target New MoA | Pre-clinical |
NovaBiotics Ltd | Nylexa™ | 3d | Other | Broad Gram +/- Priority Pathogen * Resistance breaker | New Class New Target New MoA | Pre-clinical |
NovaBiotics Ltd | Novarifyn® | 3a | Protein/Peptide | Broad Gram +/- Priority Pathogen * Gram negative and Gram negative reistant/MDR infections (ESKAPE), some Gram positive coverage | New Class New Target New MoA | Pre-clinical |
NovaBiotics Ltd | Luminaderm® | 1b | Protein/Peptide | Broad Gram +/- Priority Pathogen * MRSA | New Class New Target New MoA | Pre-clinical |
NovaBiotics Ltd | Lynovex® inhaled | 1a | Other | Broad Gram +/- Priority Pathogen * Cystic Fibrosis | New Class New Target New MoA | IND/CTA ready |
NovaBiotics Ltd | Novexatin® | 3a | Protein/Peptide | Non Bacterial Target Priority Pathogen * Onychomycosis | New Class New Target New MoA | Phase II |
NovaBiotics Ltd | Lynovex® oral | 3b | Other | Broad Gram +/- Priority Pathogen * Cystic Fibrosis | New Class New Target New MoA | Phase II |
Nosopharm | NOSO-2G | 3a | NME | Broad Gram +/- Priority Pathogen * Hospitalacquired or Ventilatoracquired bacterial pneumoniae (HABP/VABP) | New Class New Target New MoA | Lead opt |
Nosopharm | NOSO-502 | 3a | NME | Gram - Priority Pathogen * Complicated urinary tract infections (cUTI) | New Class New Target New MoA | IND/CTA ready |
Northern Antibiotics Oy (Ltd) | NAB815 | 3a | Protein/Peptide | Gram - Priority Pathogen * cUTI caused by MDR Gram-negatives | | Pre-clinical |
Northern Antibiotics Oy (Ltd) | NAB739 | 3a | Protein/Peptide | Gram - Priority Pathogen * cUTI caused by MDR Gram-negatives | | Pre-clinical |
Nabriva Therapeutics GmbH | Lefamulin | 3a | NME | Broad Gram +/- Priority Pathogen * ABSSSI | New Class New Target New MoA | Phase II |
Nabriva Therapeutics GmbH | Lefamulin | 3a | NME | Broad Gram +/- Priority Pathogen * STIs, HABP/VABP, Osteomyelitis, Prosthetic Joint Infections | New Class New Target New MoA | Pre-clinical |
Nabriva Therapeutics GmbH | Lefamulin | 3a | NME | Broad Gram +/- Priority Pathogen * Pediatric Indications | New Class New Target New MoA | Phase I |
Nabriva Therapeutics GmbH | Lefamulin | 3a | NME | Broad Gram +/- Priority Pathogen * CABP (community-acquired bacterial pneumonia) | New Class New Target New MoA | Phase III |
Mutabilis SAS | 2G-DABOCIN | 3a | NME | Gram - Priority Pathogen * IV treatment against Enterobacterales & non-fermenters | New Class | Lead opt |
Mutabilis SAS | EBL-1463 | 3a | NME | Gram - Priority Pathogen * IV treatment against Enterobacterales | New Class | Pre-clinical |
Madam Therapeutics BV | SAAP148 | 3a | Protein/Peptide | Broad Gram +/- Priority Pathogen * Diabetic foot ulcers, burns and MRSA carriership | New Class New Target New MoA | Pre-clinical |
IMMUNETHEP, SA | Unimab | 3c | Antibody | Broad Gram +/- Priority Pathogen * Intensive Care Units / Hospital Acquired infections | New Class New Target New MoA | Pre-clinical |
IMMUNETHEP, SA | cPNV | 1a | Vaccine | Broad Gram +/- Priority Pathogen * Preventive | New Class New Target | Pre-clinical |
Hypharm GmbH | HY-133 | 1b | Phage | Gram + Priority Pathogen * Nasal colonization with MRSA | New Class New Target New MoA | Pre-clinical |
Helperby Therapeutics Ltd | HY-001 | 3d | Other | Gram - Priority Pathogen * Urinary Tract Infections | New Class New Target New MoA | Phase II |
Helperby Therapeutics Ltd | HY-002 | 3d | Other | Gram - Priority Pathogen * Intra-Abdominal Infections | New Class New Target New MoA | Phase I |
Helperby Therapeutics Ltd | HY-004 | 1b | Other | Gram + Priority Pathogen * Nasal MRSA decolonisation | New Class New Target New MoA | Phase II |
Helperby Therapeutics Ltd | HY-005 | 3d | Other | Gram + Priority Pathogen * Skin & Soft Tissue MRSA | New Class New Target New MoA | Phase II |
Eligo Bioscience | EB004 | 1b | Other | Precise Pathogen ID Priority Pathogen * Multi-drug resistant Enterobacteriaceae | New Class New MoA | Pre-clinical |
Destiny Pharma plc | XF-73 | 3d | NME | Broad Gram +/- Priority Pathogen * Hospital pneumonia/ventilator-associated pneumonia (VAP) | New Class New Target New MoA | Pre-clinical |
Destiny Pharma plc | XF-70 | 1b | NME | Broad Gram +/- Priority Pathogen * Bacterial biofilm-infections | New Class New Target New MoA | Pre-clinical |
Destiny Pharma plc | XF-73 | 1b | NME | Broad Gram +/- Priority Pathogen * Prevention of post-surgical infection | New Class New Target New MoA | Phase II |
DEINOVE | DNV3837 | 3a | NME | Broad Gram +/- Priority Pathogen * C.difficile gastrointestinal infections | New Class New MoA | Phase II |
Debiopharm International | Debio 1453 | 3a | NME | Gram - Priority Pathogen * N. gonorrhoeae infections | New Class New Target New MoA | Lead opt |
Debiopharm International | Afabicin (Debio 1450) | 3a | NME | Precise Pathogen ID Priority Pathogen * ABSSSI, Bone & Joint Infections (BJIs) | New Class New Target New MoA | Phase II |
Combioxin SA | CAL02 | 4a | Other | Broad Gram +/- Priority Pathogen * Severe infections | New Class New Target New MoA | Phase II |
Centauri Therapeutics Ltd | ABX01 | 3c | Other | Gram - Priority Pathogen * Broad spectrum Gram negative, including clinically-relevant strains of Enterobacteriaceae, P. aeruginosa, and A. baumannii | New Class New Target New MoA | Pre-clinical |
Centauri Therapeutics Ltd | ABX02 | 3c | Other | Precise Pathogen ID Priority Pathogen * Pseudomonas Aeruginosa specific Inhibitor | New Class New Target New MoA | Pre-clinical |
BioVersys AG | BV200 | 4a | NME | Gram + Priority Pathogen * Anti-toxin for Staphylococcus aureus | New Class New Target New MoA | Lead opt |
BioVersys AG | BV300 | 3a | NME | Gram - Priority Pathogen * Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | New Class New Target New MoA | Lead opt |
BioVersys AG | BVL-GSK098 | 3d | NME | Precise Pathogen ID Priority Pathogen * Adjuvant reversing resistance and potentiating Ethionamide activity in Tuberculosis | New Class New Target New MoA | Phase I |
BioFilm Pharma | BFP002 | 3e | NME | Broad Gram +/- Priority Pathogen * Staphylococcus aureus, Pseudomonas aeruginosa Systemic – Cystic Fibrosis | New Target New MoA | Lead opt |
BioFilm Pharma | BFP101 | 3e | NME | Gram + Priority Pathogen * Staphylococcus aureus Local - Diabetic Foot Ulcer, Joint & Bone Infections | New Target New MoA | Lead opt |
BioFilm Pharma | BFP102 | 3e | NME | Broad Gram +/- Priority Pathogen * Staphylococcus aureus, Pseudomonas aeruginosa Systemic – Cystic Fibrosis | New Class New Target New MoA | Lead opt |
BioFilm Pharma | BFP001 | 3e | NME | Gram + Priority Pathogen * Staphylococcus aureus Local - Diabetic Foot Ulcer, Joint & Bone Infections | New Class New Target New MoA | Lead opt |
Basilea | Ceftobiprole | 3a | NME | Broad Gram +/- Priority Pathogen * Acute bacterial skin and skin structure infections, Staphylococcus aureus bacteremia | | Phase III |
Basilea | Ceftobiprole | 3a | NME | Broad Gram +/- Priority Pathogen * Community- and hospital-acquired pneumonia (excluding ventilator-associated pneumonia) | | Marketed |
ANTABIO S.A.S | ANT_Pei | 3c | NME | Precise Pathogen ID Priority Pathogen * Pseudomonas infections in Cystic Fibrosis patients | New Class New Target New MoA | Pre-clinical |
ANTABIO S.A.S | ANT2681 | 3d | NME | Gram - Priority Pathogen * Hospital-acquired infections caused by carbapenem-resistant Enterobacteriaceae (CRE) [cUTI, cIAI, Nosocomial Pneumonia] | New Class New Target New MoA | Pre-clinical |
Alphanosos | W16P0576 | 3e | Other | Broad Gram +/- Priority Pathogen * A. baumannii, P. aeruginosa, MRSA,N. gonorrhoeae, M. tuberculosis - Infectious skin conditions (eczema, acne, sporiasis, ...), difficult wounds | New Class New Target New MoA | Pre-clinical |
ALLECRA THERAPEUTICS | Cefepime / Enmetazobactam | 3d | NME | Broad Gram +/- Priority Pathogen * cUTI, cIAI, HAP | | Phase II |
Akthelia | HO53/HO56 ADP | 3c | NME | Broad Gram +/- Priority Pathogen * Multidrug resistant lung infections including nosocomial infections (K. pneumoniae) | New Class New Target New MoA | Lead opt |
AiCuris Anti-infective Cures AG | Artilysins | 3a | Protein/Peptide | Gram - Priority Pathogen * Undisclosed | New Class New MoA | Lead opt |
AGILeBiotics B.V. | ABX-395 | 3a | NME | Gram - Priority Pathogen * Hospital-treated MDR Gram-negative infections | | Lead opt |
AGILeBiotics B.V. | ABX-605 (Toframicin) | 3a | NME | Gram - Priority Pathogen * Hospital-treated MDR Gram-negative infections | | Pre-clinical |
ABAC therapeutics | ABAC-39,877 | 3a | NME | Gram - Priority Pathogen * Infections by MDR/XDR A baumannii, including ColistinR and CarbapenemR | New Class New Target New MoA | Pre-clinical |
Da Volterra | DAV121 | 4b | Other | Broad Gram +/- Priority Pathogen * Prevention of gut microbiota antibiotic-dysbiosis and emergence of resistance to β-lactam antibiotics, including carbapenems | New Class New Target New MoA | Lead opt |
Da Volterra | DAV132 | 4b | Other | Broad Gram +/- Priority Pathogen * Prevention of C.difficile infections | New Class New Target New MoA | Phase II |